Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease

Pereira, Evelyn Nunes Goulart da Silva; Silvares, Raquel Rangel; Flores, Edgar Eduardo Ilaquita; Rodrigues, Karine Lino; Ramos, Isalira Peroba; Silva, Igor José da; Machado, Marcelo Pelajo; Miranda, Rosiane Aparecida; Pazos-Moura, Carmen Cabanelas; Albuquerque, Cassiano F. Gonçalves de; Faria Neto, Hugo Caire de Castro; Tibiriçá, Eduardo; Daliry, Anissa.
Artículo en Inglés | ARCA | ID: arc-23215

Documentos relacionados

  1. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
  2. Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
  3. [Thyroid dysfunction and soft fatty liver disease].
  4. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease.
  5. Role of High-Mobility Group Box-1 in Liver Pathogenesis.
  6. [Diagnosis and therapeutic strategies for non-obese type of non-alcoholic fatty liver diseases].
  7. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
  8. The Relevance of Toxic AGEs (TAGE) Cytotoxicity to NASH Pathogenesis: A Mini-Review.
  9. Hepatic Autonomic Nervous System and Neurotrophic Factors Regulate the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease.
  10. Future therapy for non-alcoholic fatty liver disease.